Topics

Galapagos, MorphoSys, Novartis end development of experimental atopic dermatitis drug MOR106 http://www.firstwordpharma.com/node/1677060  $GLPG $MOR $NVS

05:10 EDT 29 Oct 2019 | FirstWord Pharma

Galapagos, MorphoSys, Novartis end development of experimental atopic dermatitis drug MOR106 http://www.firstwordpharma.com/node/1677060 

Original Article: Galapagos, MorphoSys, Novartis end development of experimental atopic dermatitis drug MOR106 http://www.firstwordpharma.com/node/1677060  $GLPG $MOR $NVS

NEXT ARTICLE

More From BioPortfolio on "Galapagos, MorphoSys, Novartis end development of experimental atopic dermatitis drug MOR106 http://www.firstwordpharma.com/node/1677060  $GLPG $MOR $NVS"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Eczema
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...